Novo Nordisk A/S may be best known for its diabetes and obesity businesses, but the Danish group is determined to make its presence more keenly felt in the rare diseases space; an area in which it has been active for over four decades.
The Copenhagen-headquartered group announced at a recent capital markets day that it has changed the name of its biopharm franchise to Novo Nordisk Rare Disease. The new division is headed by Ludovic Helfgott who told In Vivo that "we decided to take this experience accumulated for 40 years and really turn it into an asset
